Cannabis cultivator Broken Coast, a Tilray brand, has launched Platinum Pavé, a new indica strain boasting a rich terpene profile and potent THC. Grown using meticulous techniques, this small-batch cultivar is initially available in British Columbia, with wider distribution planned for 2024.
Tilray Brands (TLRY) faces a mixed outlook according to Zuanic & Associates, despite its strong balance sheet and diverse global presence. While its international expansion, particularly in Germany, is showing promise, rising costs and market share losses in Canada raise concerns. The company’s strategic focus on the U.S. beverage market with acquired craft beer brands presents potential for growth, but revenue targets remain elusive. Zuanic advises investors to hold off for now, awaiting clearer signs of sustainable growth and improved operational efficiency.
Tilray Brands CEO Irwin Simon believes the 2024 US presidential elections will bring positive regulatory changes for the cannabis industry regardless of the winner. Both candidates have expressed support for legalization, and Tilray is already seeing promising financial results with a 13% increase in revenue for the first quarter of fiscal 2025.
Canadian cannabis giant Tilray Brands is entering the booming hemp-derived THC beverage market with a new line of mocktails, seltzers, and sparkling beverages. The company’s move positions them to capitalize on rising consumer demand for alternative adult beverages.
Tilray Medical, a division of Tilray Brands, has expanded its presence in Australia with the launch of Redecan EU-GMP certified medical cannabis products, offering patients in Australia a wider selection of premium quality medical cannabis options.
Tilray Brands, Inc. (TLRY) has acquired a promissory note from Double Diamond Holdings Ltd (DDH) for $23.8 million. In exchange, Tilray issued 13,217,588 shares of its common stock to DDH. This acquisition comes shortly after Tilray’s successful acquisition of Atwater Brewery, adding to its growing craft beer portfolio. This deal positions Tilray as a top player in the US craft beer market, with the company expecting a 30% growth in its beer business.
A new study by Tilray Medical, a division of Tilray Brands, shows positive results in using cannabinoid treatments for patients with fibromyalgia. The study, titled ‘Treatment in Pain Management and Other Fibromyalgia-Associated Symptoms: A Case Series (TOMAS),’ examined the impact of Tilray Dried Flower THC18 on chronic pain, sleep, and quality of life. The findings suggest that cannabinoids could be a promising and cost-effective treatment option for fibromyalgia patients.
Tilray Brands has released a new indica strain, ‘Milk & Cookies’, under its Broken Coast brand, while simultaneously expanding its U.S. brewery business through the acquisition of four craft breweries from Molson Coors.
Germany’s cannabis market is rapidly expanding, with Tilray, Aurora, and Demecan emerging as key players in domestic cultivation. These companies are strategically positioned to capitalize on the growing medical cannabis market, projected to reach €1.7 billion by 2025. This article delves into the operations and contributions of each company, highlighting their role in shaping Germany’s cannabis landscape.
